Why We Decided Not To Abandon the Amgen and Illumina Band Wagons

Contrary to our expectations Amgen’s (AMGN) shares declined more than 10% in 2019, instead of rallying. Part of the decline followed the threat of devastating the large drug creators and developers by lowering the high prices of drugs. Amgen’s stock loss can also be attributed to the pressure exerted by negative investors on the stock.  

Today, after . . .

This content is for paid subscribers.
Please click here to subscribe or here to log in.